Medivation spies out immune-oncology territory with CureTech deal

Medivation is venturing into the immune-oncology arena, licensing CureTech's late-stage anti PD-1 monoclonal antibody pidilizumab (CT-011), in an effort to diversify its portfolio, currently dominated by the prostate cancer treatment Xtandi (enzalutamide; licensed to Astellas).

Medivation is venturing into the immune-oncology arena, licensing CureTech's late-stage anti PD-1 monoclonal antibody pidilizumab (CT-011), in an effort to diversify its portfolio, currently dominated by the prostate cancer treatment Xtandi (enzalutamide; licensed to Astellas).

Under the agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category